Overview Dividends

(ARE) Alexandria Real Estate - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0152711091

Laboratories, Offices, Campuses, Venture Capital

ARE EPS (Earnings per Share)

EPS (Earnings per Share) of ARE over the last years for every Quarter: "2020-09": 0.56, "2020-12": 0.62, "2021-03": 0.72, "2021-06": 0.73, "2021-09": 0.7, "2021-12": 0.58, "2022-03": 0.71, "2022-06": 0.78, "2022-09": 0.35, "2022-12": 0.31, "2023-03": 0.83, "2023-06": 0.51, "2023-09": 0.87, "2023-12": 0.82, "2024-03": 0.89, "2024-06": 0.88, "2024-09": 0.87, "2024-12": 0.69, "2025-03": 0.51, "2025-06": 0.48, "2025-09": 0.5,
EPS Growth (3Y CAGR): 18.99%
EPS Trend (3Y Correlation): -2.4%

ARE Revenue

Revenue of ARE over the last years for every Quarter: 2020-09: 545.042, 2020-12: 463.72, 2021-03: 479.849, 2021-06: 509.619, 2021-09: 547.759, 2021-12: 576.923, 2022-03: 615.065, 2022-06: 643.764, 2022-09: 659.852, 2022-12: 670.281, 2023-03: 687.949, 2023-06: 704.339, 2023-09: 707.531, 2023-12: 742.637, 2024-03: 755.551, 2024-06: 755.162, 2024-09: 775.744, 2024-12: 763.249, 2025-03: 743.175, 2025-06: 762.04, 2025-09: 751.944,
Revenue Growth (3Y CAGR): 4.27%
Revenue Trend (3Y Correlation): 82.9%

Description: ARE Alexandria Real Estate October 31, 2025

Alexandria Real Estate Equities (NYSE: ARE) is a S&P 500 life-science REIT that owns, operates, and develops “Megacampus” clusters in premier biotech hubs such as Boston, the Bay Area, San Diego, Seattle, Maryland, the Research Triangle, and New York City. As of 30 June 2025 the company’s market cap is roughly $25.7 billion and it controls about 39.7 million rentable square feet (RSF) of operating space plus an additional 4.4 million RSF of Class A/A+ assets under construction, with one fully pre-leased project slated to break ground within the next year.

Key performance indicators from the most recent quarterly release show an occupancy rate near 96 % and a funds-from-operations (FFO) growth of 7 % year-over-year, driven by strong lease-rate escalations (≈5 % YoY) and a tenant mix weighted toward high-margin biotech and pharma firms. The REIT’s leverage remains moderate at roughly 45 % debt-to-EBITDA, reflecting its disciplined underwriting. Sector-wide, the life-science real-estate market is buoyed by a 12 % annual increase in U.S. biotech venture capital funding and sustained federal R&D spending, which together underpin demand for premium lab and office space.

For a deeper quantitative comparison of Alexandria’s valuation metrics against peers, the ValueRay platform offers a convenient dashboard for further analysis.

ARE Stock Overview

Market Cap in USD 9,742m
Sub-Industry Diversified REITs
IPO / Inception 1997-05-27

ARE Stock Ratings

Growth Rating -81.4%
Fundamental 62.7%
Dividend Rating 74.8%
Return 12m vs S&P 500 -57.2%
Analyst Rating 3.54 of 5

ARE Dividends

Dividend Yield 12m 9.69%
Yield on Cost 5y 4.18%
Annual Growth 5y 5.18%
Payout Consistency 96.0%
Payout Ratio 2.4%

ARE Growth Ratios

Growth Correlation 3m -23.6%
Growth Correlation 12m -68.5%
Growth Correlation 5y -86.7%
CAGR 5y -24.05%
CAGR/Max DD 3y (Calmar Ratio) -0.38
CAGR/Mean DD 3y (Pain Ratio) -0.77
Sharpe Ratio 12m 0.24
Alpha -72.93
Beta 1.319
Volatility 70.70%
Current Volume 3105.4k
Average Volume 20d 1933k
Stop Loss 51.9 (-4.7%)
Signal -1.00

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-415.7m TTM) > 0 and > 6% of Revenue (6% = 181.2m TTM)
FCFTA 0.04 (>2.0%) and ΔFCFTA 0.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -45.63% (prev -55.26%; Δ 9.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.04 (>3.0%) and CFO 1.38b > Net Income -415.7m (YES >=105%, WARN >=100%)
Net Debt (-579.5m) to EBITDA (1.39b) ratio: -0.42 <= 3.0 (WARN <= 3.5)
Current Ratio 0.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (170.1m) change vs 12m ago -1.12% (target <= -2.0% for YES)
Gross Margin 69.19% (prev 70.57%; Δ -1.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 7.96% (prev 7.87%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.21 (EBITDA TTM 1.39b / Interest Expense TTM 161.8m) >= 6 (WARN >= 3)

ValueRay F-Score (Strict, 0-100) 62.66

1. Piotroski 2.50pt = -2.50
2. FCF Yield 6.28% = 3.14
3. FCF Margin 45.55% = 7.50
4. Debt/Equity 0.61 = 2.32
5. Debt/Ebitda -0.42 = 2.50
6. ROIC - WACC (= -4.82)% = -6.02
7. RoE -2.26% = -0.38
8. Rev. Trend 82.85% = 6.21
9. EPS Trend -2.43% = -0.12

What is the price of ARE shares?

As of November 06, 2025, the stock is trading at USD 54.47 with a total of 3,105,403 shares traded.
Over the past week, the price has changed by -7.30%, over one month by -31.90%, over three months by -29.18% and over the past year by -49.12%.

Is Alexandria Real Estate a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Alexandria Real Estate is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 62.66 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARE is around 43.85 USD . This means that ARE is currently overvalued and has a potential downside of -19.5%.

Is ARE a buy, sell or hold?

Alexandria Real Estate has received a consensus analysts rating of 3.54. Therefor, it is recommend to hold ARE.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 9
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ARE price?

Issuer Target Up/Down from current
Wallstreet Target Price 90.3 65.8%
Analysts Target Price 90.3 65.8%
ValueRay Target Price 47.3 -13.1%

ARE Fundamental Data Overview November 01, 2025

Market Cap USD = 9.74b (9.74b USD * 1.0 USD.USD)
P/E Forward = 16.6945
P/S = 3.1854
P/B = 0.832
P/EG = 844.2
Beta = 1.319
Revenue TTM = 3.02b USD
EBIT TTM = 34.6m USD
EBITDA TTM = 1.39b USD
Long Term Debt = 12.24b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.10b USD (from shortTermDebt, two quarters ago)
Debt = 12.75b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -579.5m USD (from netDebt column, last quarter)
Enterprise Value = 21.91b USD (9.74b + Debt 12.75b - CCE 579.5m)
Interest Coverage Ratio = 0.21 (Ebit TTM 34.6m / Interest Expense TTM 161.8m)
FCF Yield = 6.28% (FCF TTM 1.38b / Enterprise Value 21.91b)
FCF Margin = 45.55% (FCF TTM 1.38b / Revenue TTM 3.02b)
Net Margin = -13.76% (Net Income TTM -415.7m / Revenue TTM 3.02b)
Gross Margin = 69.19% ((Revenue TTM 3.02b - Cost of Revenue TTM 930.5m) / Revenue TTM)
Gross Margin QoQ = 68.18% (prev 70.55%)
Tobins Q-Ratio = 0.59 (Enterprise Value 21.91b / Total Assets 37.38b)
Interest Expense / Debt = 0.43% (Interest Expense 55.3m / Debt 12.75b)
Taxrate = 21.0% (US default 21%)
NOPAT = 27.3m (EBIT 34.6m * (1 - 21.00%))
Current Ratio = 0.30 (Total Current Assets 579.5m / Total Current Liabilities 1.96b)
Debt / Equity = 0.61 (Debt 12.75b / totalStockholderEquity, last quarter 21.06b)
Debt / EBITDA = -0.42 (Net Debt -579.5m / EBITDA 1.39b)
Debt / FCF = -0.42 (Net Debt -579.5m / FCF TTM 1.38b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.11% (Net Income -415.7m / Total Assets 37.38b)
RoE = -2.26% (Net Income TTM -415.7m / Total Stockholder Equity 18.40b)
RoCE = 0.11% (EBIT 34.6m / Capital Employed (Equity 18.40b + L.T.Debt 12.24b))
RoIC = 0.09% (NOPAT 27.3m / Invested Capital 30.39b)
WACC = 4.91% (E(9.74b)/V(22.49b) * Re(10.88%) + D(12.75b)/V(22.49b) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 10.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.28%
[DCF Debug] Terminal Value 58.84% ; FCFE base≈1.33b ; Y1≈874.9m ; Y5≈400.1m
Fair Price DCF = 30.68 (DCF Value 5.30b / Shares Outstanding 172.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -2.43 | EPS CAGR: 18.99% | SUE: 0.62 | # QB: 0
Revenue Correlation: 82.85 | Revenue CAGR: 4.27% | SUE: -0.13 | # QB: 0

Additional Sources for ARE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle